Showing results (1721-1730 of 1,851) with videos related to

Sort By:
Pageof 186
Neuromuscular Disorders : NMD|February 20, 2025
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophyLeo H Wang, Maya N Hatch, Michael P McDermott, et al.
Stem Cell Research|September 14, 2019
Generation of genetically matched hiPSC lines from two mosaic facioscapulohumeral dystrophy type 1 patientsErik van der Wal, Bianca den Hamer, Patrick J van der Vliet, et al.
Plos Genetics|April 18, 2013
Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHDYvonne D Krom, Peter E Thijssen, Janet M Young, et al.
American Journal of Human Genetics|October 1, 2013
The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1Sabrina Sacconi, Richard J L F Lemmers, Judit Balog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
Nature Medicine|November 26, 2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A Engelman, Liang Chen, Xiaohong Tan, et al.
Physical Chemistry Chemical Physics : PCCP|January 18, 2019
Experimental and computational studies of Criegee intermediate reactions with NH3 and CH3NH2Rabi Chhantyal-Pun, Robin J Shannon, David P Tew, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial designChao-Jen Wong, Seth D Friedman, Lauren Snider, et al.
Neurology|February 12, 2016
Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysisValeria A Sansone, James Burge, Michael P McDermott, et al.
Pageof 186